Longeveron Inc. (LGVN)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$15.8M
Cash & Equivalents
$4.4M
Quarterly Burn Rate
11 mo
Est. Cash Runway
$21M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT04925024 Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial... PHASE2 Active Not Recruiting 40

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for LGVN.

SEC EDGAR Filings

All SEC filings for Longeveron Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.